کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله
Original Article

Relation of resistin levels with C-reactive protein, homocysteine and uric acid in smokers and non-smokers

Onur Esbah¹, Gül Gürsöy², Nazli Gulsoy Kirnap¹, Hacer Cetiner¹,
Berrin Demirbaş³, Yasar Acar¹, Murat Bayram¹

Abstract

BACKGROUND: The association between C-reactive protein, homocysteine, uric acid levels and cardiovascular risk have been debated for decades. Resistin is a newly discovered adipocyte derived cytokine. Smoking besides its effect on atherosclerosis, is shown to alter adipocytokine levels. Bearing in mind, these complex relationship of resistin with smoking, C-reactive protein, homocysteine and uric acid, we planned to investigate the association of resistin and these cardiovascular risk factors in smoker and non-smoker subjects.

METHODS: We conducted a cross-sectional randomized study including 52 smoking and 33 non-smoking men. After making comparisons of C-reactive protein, homocysteine, uric acid and resistin between the two groups, we classified the subjects according to their insulin resistance and body mass and made again the comparisons.

RESULTS: Resistin levels were higher in smokers than in non-smokers (p<0.001) and also in insulin resistant than in non-insulin resistant smokers (p<0.05). Resistin levels were indifferent in non-smokers as insulin resistance was concerned and in smoker or non-smokers as body mass index was concerned. As all subjects were grouped based on homeostasis model assessmen index and body mass index, neither C-reactive protein nor homocysteine and uric acid levels differs.

CONCLUSIONS: We found that smoking may have influence on resistin levels and in smokers, insulin resistance is related to resistin levels, but in smoker and non-smokers body mass may not have any association with resistin. Resistin also may not have a role in C-reactive protein, homocysteine and uric acid levels both in smokers and non-smokers.

KEYWORDS: CRP, Homocysteine, Uric Acid, Resistin, Smoking.

J Res Med Sci 2011; 16(10): 1273-1279

Atherosclerosis is an inflammatory disease which is initiated in early childhood in the vascular intima.¹ It has been accepted that atherosclerosis has traditional risk factors, such as age, family history, ethnicity, gender, smoking, hypertension, hyperlipidemia, diabetes, obesity, sedentary life and mental stress. Nowadays, new risk factors are considered such as, C-reactive protein (CRP), homocysteine and uric acid.

CRP is a sensitive marker of inflammation.² Although it is unknown whether CRP is involved in coronary heart disease pathogenesis,³,⁴ elevated serum CRP levels are associated with cardiovascular risk factors and obesity.⁵,⁶ Eversince McCully was the first to draw attention to the relationship between homocysteine and atherosclerosis in 1967, plasma homocysteine levels were widely accepted as an independent risk factor in cardiovascular disease.⁷,⁸ Likewise, the association between increased serum uric acid levels and cardiovascular risk have been debated for decades and studies have provided conflicting results regarding the
clinical significance of serum uric acid levels in cardiovascular events. It is shown that smoking alters adipocytokine levels which are associated with insulin resistance, type 2 diabetes, atherosclerosis and cardiovascular disease. Adipocytokines play a significant role in pathogenesis of low grade inflammation associated with type 2 diabetes, obesity, metabolic syndrome, insulin resistance and in chronic inflammatory and autoimmune diseases. Resistin is a recently found adipocytokine. The subject of its role in insulin resistance, obesity and type 2 diabetes mellitus (T2DM) in human is conflicting.

Keeping in mind these complex associations among CRP, homocysteine, uric acid, atherosclerosis, obesity, insulin resistance and resistin, we planned to seek the relation between resistin levels and CRP, homocysteine, uric acid after controlling smoking behavior and insulin resistance and body mass index.

**Methods**

**Subjects**

A total of 52 male smokers aged 25-45 years (36.8±6.8), were recruited from the outpatient Clinic of Ankara Education and Research Hospital from January 2009 to May 2009. 33 aged matched (36.7 ± 7.2) male subjects formed the control group. This was a cross-sectional study, and subjects were selected randomly. As resistin serum and mRNA levels were significantly higher in females than in males at all ages, in order to obtain an homogenous group we examined only males. Smokers have been smoking at least for 2 years and at least ten cigarettes daily.

Subjects with female gender, hypertension, diabetes mellitus, glucose intolerance, hyperlipidemia, conditions which may affect metabolic parameters (such as thyroid dysfunctions in past history or nowadays), chronic diseases, infection and coronary artery disease were excluded.

After detailed physical examination, in all subjects body weight and height were measured. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Blood was withdrawn after 12 h of overnight fasting, at 08.30 a.m. for CRP, homocysteine, uric acid and resistin levels.

This study was performed according to the Helsinki declaration 2008. The local ethics committee approved this study and all the subjects gave written informed consent.

**Methods**

An indirect measure of insulin resistance was calculated from the fasting plasma insulin (µunite/ml) x fasting plasma glucose (mmol/l)/22.5 formula as homeostasis model assessment of insulin resistance (HOMA-IR). As in normal person HOMA-IR level was stated to be < 2.7, it was chosen a cut-point for insulin resistance.

High sensitivity C-reactive protein (CRP) was measured by immunnoflowmetric tests by Beckman-Cutler device. Homocysteine concentrations were determined according to the method of HPLC using Agilend 1100 device. Uric acid was measured by calorimetric methods.

For the measurements of resistin, after fasting blood samples were drawn, they were put into a dry tube, and were santrifuged, 5000 cycle/min in 10 minutes. Serum was then seperated and placed in another dry tube before storing at -80˚C. Serum resistin levels were evaluated by a commercial resistin ELISA kit.

**Statistical analysis**

Calculations were performed using SPSS version 11.5 (Customer ID 30000105930). Data were presented as mean ± SD. Student t-test was used to compare the groups in a parametric way. A p value of < 0.05 was considered as statistically significant. Pearson correlation coefficient was used for the correlation analysis.
Results
In smoker group, resistin levels were statistically found higher than in non-smoker group (p<0.001). There were no difference in CRP, homocysteine and uric acid levels between the two groups (Table 1).

As smoker group was grouped according to their HOMA-IR levels, subjects with HOMA-IR<2.7 had lower resistin levels than subjects with HOMA-IR ≥ 2.7 (p < 0.05). CRP, homocysteine and uric acid levels were not different (Table 2). When non-smoker group was grouped as HOMA-IR, subjects with HOMA-IR<2.7 and HOMA-IR≥2.7 did not show any statistically different parameters (Table 2).

If smoker group was classified based on their BMI, neither CRP, homocysteine and uric acid nor resistin levels were found statistically different between the subgroups (Table 3). In non-smoker group no difference in any parameter was found when BMI was used to divide it into subgroups. (Table 3).

When we made the correlation analysis of smoker and non-smoker group, we did not find any positive or negative correlations between CRP, homocysteine, uric acid and resistin.

Discussion
We planned to find out if the interesting adipocytokine, resistin is associated with newly accepted atherosclerotic markers such as CRP, homocysteine and uric acid in subjects who smoke or do not. We found that in smokers with insulin resistance serum resistin levels were high, but between the two groups who smoked or did not smoke, who had insulin resistance or did not have, and who were obese or were not obese, CRP, homocysteine and uric acid levels were not different.

Cardiovascular disease accounts for nearly 40% of all deaths each year. The factors that make up the Framingham risk score (age, sex, blood pressure, serum total or low density lipoprotein cholesterol level, high density lipoprotein cholesterol level, smoking and diabetes) account for most of the excess risk for incident coronary heart disease. However, these factors do not explain all of the excess risk, so some markers have received attention as new or emerging risk factors that could account for some of the unexplained variability in cardiovascular heart disease, such as CRP, homocysteine or uric acid.

Table 1. Results of tests in smoker and non-smoker groups

|                | SMOKER n:52 | NON-SMOKER n:33 | P   |
|----------------|-------------|-----------------|-----|
| CRP (mg/dl)    | 3.32±4.20   | 2.34±1.85       | NS  |
| Hcy (mmol/ml)  | 14.60±10.35 | 11.86±3.76      | NS  |
| Uric acid (mg/dl) | 4.62±1.35  | 4.37±1.27       | NS  |
| Resistin (ng/ml)| 5.79±2.58   | 3.25±1.40       | <0.001 |

CRP: C-reactive protein. Hcy: Homocysteine. HOMA-IR: Homeostasis model assessment-Insulin resistance index. NS: Statistically non-significant. The results are presented as Mean ± SD.

Table 2. Characteristics of smoker and non-smoker group whose Homeostasis model assessment-Insulin resistance index was <2.7 vs. HOMA-IR≥2.7.

| Smoker | HOMA-IR<2.7 | HOMA-IR≥2.7 | P   | HOMA-IR<2.7 | HOMA-IR≥2.7 | P   |
|--------|-------------|-------------|-----|-------------|-------------|-----|
| N:22   | N:30        |             |     | n:19        | n:14        |     |
| CRP (mg/dl) | 2.63±2.58 | 3.83±5.06 | NS  | 2.49±2.21   | 2.13±1.26   | NS  |
| Hcy (mmol/ml) | 14.23±9.33 | 14.88±11.18 | NS  | 11.51±3.50  | 12.32±4.17  | NS  |
| Uric acid (mg/dl) | 4.57±1.27 | 4.66±1.42 | NS  | 4.06±0.82   | 4.80±1.64   | NS  |
| Resistin (ng/ml) | 4.84±2.04 | 6.48±2.74 | <0.05 | 3.05±1.41 | 3.53±1.38 | NS  |

CRP: C-reactive protein. Hcy: Homocysteine. HOMA-IR: Homeostasis model assessment-Insulin resistance index. NS: Statistically non-significant. The results are presented as Mean ± SD.
Table 3. Characteristics of smoker and non-smoker groups when body mass index was < 27 vs. BMI≥27.

|                  | Smoker BMI<27 n:33 | Smoker BMI≥27 n:19 | Non-smoker BMI<27 n:14 | Non-smoker BMI≥27 n:19 | P     |
|------------------|---------------------|--------------------|------------------------|------------------------|-------|
| CRP (mg/dl)      | 3.39±4.83           | 3.21±292           | 1.86±1.65              | 2.68±1.96              | NS    |
| Hcy (mmol/ml)    | 12.7±5.76           | 17.8±15.05         | 12.16±3.40             | 11.6±3.40              | NS    |
| Uric Acid (mg/dl)| 4.34±1.18           | 4.11±1.51          | 4.02±0.74              | 4.63±1.52              | NS    |
| Resistin (ng/ml) | 4.72±2.55           | 5.90±2.69          | 3.33±1.58              | 3.20±1.29              | NS    |

CRP: C-reactive protein, Hcy: Homocysteine, BMI: Body mass index. NS: Statistically non-significant. The results are presented as Mean ± SD.

CRP, a pentameric protein produced by the liver, has emerged as the golden marker for inflammation. When measured in blood, CRP proved to be a strong and independent predictor of cardiovascular disease even in healthy asymptomatic subjects. A direct comparison of CRP and low density lipoprotein cholesterol (LDL-C) showed that CRP is a more valuable predictor for cardiovascular events and death, compared to LDL-C.

Although the casual relationship between hyperhomocysteinemia and cardiovascular mortality and morbidity is not so clear, consistent findings from a large number of studies strongly support an association between homocysteine level and cardiovascular events. However, in some studies a positive correlation between plasma homocysteine levels and severity of coronary lesions was also determined.

Uric acid is a novel cardiovascular risk factor, but its use as an independent risk factor for so-called disease still remains controversial. In concordance with the studies claiming that increased uric acid levels were associated with an increase in coronary heart disease risk, use of allopurinol has been shown to be related with reduced mortality risk and with reduced blood pressure in some trials.

Smoking is well established as a casual factor in coronary heart disease and stroke. Furthermore, large studies suggested that smoking is associated with the development of type 2 diabetes in men and women consistent with evidence linking smoking and insulin resistance. Smoking subjects with impaired glucose tolerance and diabetes appeared more insulin resistant than their non-smoking counterparts. Smoking also alters levels of adipocytokines.

Adipocyte related resistin is a circulating protein implicated in insulin resistance in rodents, but the role of human resistin is uncertain because it is produced also by macrophages. Besides its role in inflammation, some papers reported that in humans, plasma resistin levels correlate with obesity, insulin resistance and type 2 diabetes, while other authors failed to observe any correlation of plasma resistin levels with metabolic or anthropometric parameters. Different explanations could account for these discrepancies including the use of different assay methods, low number of patients enrolled in the different studies and the definition used to select patients. Bearing in mind the relationship of atherosclerosis with inflammation, a number of studies investigated the association of resistin with inflammatory markers such as CRP and also resistin was found to be related to coronary artery calcification.

The results of current study may have several important implications. First, our findings confirm that smoking elevates the levels of resistin. Second, in smokers resistin levels are associated with insulin resistance, but in non-smokers resistin does not differ when insulin resistance is present or absent. Third, in smoker or in non-smoker subjects if obesity exists or not, resistin levels are not significantly different. Fourth, disputatious
atherosclerotic markers such as CRP, homocysteine or uric acid are not statistically high in smokers than in non-smoker counterparts. Also, in smoker subjects, insulin resistance or obesity did not alter the levels of these markers. In non-smokers, the result is the same. Fifth, CRP, homocysteine or uric acid are not correlated with serum resistin concentrations neither in smokers nor in non-smokers.

Smoking is associated with increased plasma homocysteine levels, and both are associated with an increased risk of cardiovascular disease.\(^{50}\) It was also determined that passive smoke exposure in never-smokers is positively and independently associated with plasma homocysteine levels in a dose-dependent manner, probably pointing out the link between passive smoking and cardiovascular events.\(^{50}\) It was also shown that male gender was independently associated with elevated homocysteine levels.\(^{51}\) Aging was also demonstrated to be accompanied by elevated homocysteine.\(^{52}\) Having two risk factors about hyperhomocysteinemia, such as male gender and smoking, we awaited to find higher levels of homocysteine in our smoking male subjects, but we could not find any statistically significant difference between the groups. Homocysteine levels of our smoking group was nonsignificantly high. Perhaps if we had formed a larger group, we would have find a satisfying result. We may also explain our results by the apparently low age of our subjects.

In discordance with previous data on the relation of resistin with inflammatory markers such as CRP,\(^{44-47}\) we failed to observe any correlation between CRP, homocysteine, uric acid and resistin. We can explain the difference in our results by a number of conditions. Primarily, our groups comprised apparently healthy men. Second, our subjects were young having the mean age of 36.8±6.8 in smokers and 36.7± 7.2 in non-smokers. Third, we measured each marker at study entry and thus could not evaluate the effects of changes in the levels of these markers over time. The discrepancy of previous results with ours may be related to the time of the measurement of the markers. We think that variation over time in levels of these markers may change the correlations.

In conclusion, we want to speculate that smoking may have influence on resistin levels and in smokers insulin resistance is related to resistin levels. Furthermore, we suggest that in smoker and non-smokers, body mass may not have any association with resistin. Our results also makes us think that this small group of atherosclerotic markers are not associated to resistin levels when the subjects smoke or not. Larger and longer studies with subjects having greater range of age and two sexes may enlighten the idea of the association of CRP, homocysteine and uric acid with resistin either in smokers or non-smokers.

**Acknowledgements**
We thank the patients.

**Conflict of Interests**
Authors have no conflict of interests.

**Authors' Contributions**
Design: Gül Gürsoy, Onur Esbah
Analysis and interpretation of the data: Gül Gürsoy, Onur Esbah, Berrin Demirbaş.
Final approval of the article: Gül Gürsoy, Onur Esbah, Nazlı Gülsoy Kırrnap, Hacer Çetiner, Berrin Demirbaş, Yaşar Acar, Murat Bayram.
Statistical expertise: Onur Esbah, Yaşar Acar.
Collection of data: Onur Esbah, Murat Bayram, Nazlı Gülsoy Kırrnap, Hacer Çetiner.
References

1. Luomala M, Paiva H, Thelen K, Laaksonen R, Saarela M, Mattila K, et al. Osteopontin levels are associated with cholesterol synthesis markers in mildly hypercholesterolaemic patients. Acta Cardiol 2007; 62(2): 177-81.

2. Pepys MB, Hirschfeld GM. C-reactive protein: a critical update. J Clin Invest 2003; 111(12): 1805-12.

3. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006; 113(17): 2128-34.

4. Hingorani AD, Shah T, Casas JP. Linking observational and genetic approaches to determine the role of C-reactive protein in heart disease risk. Eur Heart J 2006; 27(11): 1261-3.

5. Miller M, Zhan M, Havas S. High attributable risk of elevated Linking observational and genetic approaches to determine the role of C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 2005; 165(18): 2063-8.

6. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151(7): 483-95.

7. Tarkun I, Cetinarslan B, Canturk Z. Lipoprotein(a) concentrations in patients with type 2 diabetes mellitus without cardiovascular disease: relationship to metabolic parameters and diabetic complications. Nutr Metab Cardiovasc Dis 2002; 12(3): 127-31.

8. Oudi ME, Aouni Z, Mazighi C, Krichnan E, Sokolove J. Uric acid in heart disease: a new C-reactive protein? Curr Opin Rheumatol 2011; 23(2): 174-7.

9. Rodrigues TC, Maahs DM, Johnson RJ, Jalal DI, Kinney GL, Rivard C, et al. Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease. Diabetes Care 2010; 33(11): 2471-3.

10. Willi C, Bodemann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007; 298(22): 2654-64.

11. Krishnan E, Sokolove J. Uric acid in heart disease: a new C-reactive protein? Curr Opin Rheumatol 2011; 23(2): 174-7.

12. Rodrigues TC, Maahs DM, Johnson RJ, Jalal DI, Kinney GL, Rivard C, et al. Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease. Diabetes Care 2010; 33(11): 2471-3.

13. Willi C, Bodemann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007; 298(22): 2654-64.

14. Ronnemaa T, Ronnemaa EM, Puukka P, Pyorala K, Laakso M. Smoking is independently associated with high plasma insulin levels in nondiabetic men. Diabetes Care 1996; 19(11): 1229-32.

15. Nakashita Y, Nakamura M, Kitamura A, Kiyama M, Ishikawa Y, Mikami H. Relationships of cigarette smoking and alcohol consumption to metabolic syndrome in Japanese men. J Epidemiol 2010; 20(5): 391-7.

16. Al-Daghri NM, Al-Attas OS, Hussain T, Sabieo S, Bamakhramah A. Altered levels of adipocytokines in type 2 diabetic cigarette smokers. Diabetes Res Clin Pract 2009; 83(2): e37-e39.

17. Stofkova A. Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 2010; 44(1): 25-36.

18. Gursoy G, Kyrmap NG, Esbah O, Acar Y, Demirbas B, Akcayoz S. The relationship between plasma omentin-1 levels and insulin resistance in newly diagnosed type 2 diabetic women. Clin Rev Opin 2010; 2(4): 49-54.

19. Gursoy G, Alagoz S, Acar Y, Demirbas B, Cetiner H, Kilic Z. Osteopontin a new probable marker for atherosclerosis in obese women. Clin Rev Opin 2010; 2(3): 35-40.

20. Gursoy G, Akcayoz SS, Acar Y, Demirbas B. Visfatin in hyperlipidemic female patients. J Medicine Medical Sciences 2010; 1(4): 120-5.

21. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409(6818): 307-12.

22. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001; 276(14): 11252-6.

23. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000; 19(15): 4046-55.

24. Al-Harithy RN, Al-Ghamdi S. Serum resistin, adiposity and insulin resistance in Saudi women with type 2 diabetes mellitus. Ann Saudi Med 2005; 25(4): 283-7.

25. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50(10): 2199-202.

26. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration.
Resistin levels

Esbah et al

cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88(10): 4848-56.

27. Vozarova de Court, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004; 53(5): 1279-84.

28. Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab 2004; 6(3): 163-70.

29. Utschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005; 48(11): 2330-3.

30. Makimura H, Mizuno TM, Bergen H, Mobbs CV. Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Am J Physiol Endocrinol Metab 2002; 283(6): E1266-E1271.

31. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27(6): 1487-95.

32. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-47.

33. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290(7): 891-7.

34. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336(14): 973-9.

35. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347(20): 1557-65.

36. Agoston-Coldea L, Mocan T, Seicean A, Gafosse M, Rosenstingl S. The plasma homocysteine concentrations and prior myocardial infarction. Rom J Intern Med 2010; 48(1): 65-72.

37. Clarke R, Halsey J, Bennett D, Lewington S. Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. J Inherit Metab Dis 2011; 34(1): 83-91.

38. Nam GE, Lee KS, Park YG, Cho KH, Lee SH, Ko BJ, et al. An increase in serum uric acid concentrations is associated with an increase in the Framingham risk score in Korean adults. Clin Chem Lab Med 2011; 49(5): 909-14.

39. Tan Z, Dai T, Zhong X, Tian Y, Leppo MK, Gao WD. Preservation of cardiac contractility after long-term therapy with oxypurinol in post-ischemic heart failure in men. Eur J Pharmacol 2009; 621(1-3): 71-7.

40. Targher G, Alberiche M, Zenere MB, Bonadonna RC, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82(11): 3619-24.

41. Al Mutairi SS, Mojmimiyi OA, Shiah Eldeen AA, Al SA, Abdella N. Effect of smoking habit on circulating adipokines in diabetic and non-diabetic subjects. Ann Nutr Metab 2008; 52(4): 329-34.

42. Efstathiou SP, Skева II, Dimas C, Panagiotou A, Parisi K, Tzanoumis L, et al. Smoking cessation increases serum adiponectin levels in an apparently healthy Greek population. Atherosclerosis 2009; 205(2): 632-6.

43. Gomez-Ambrosi J, Fruhbeck G. Evidence for the involvement of resistin in inflammation and cardiovascular disease. Curr Diabetes Rev 2005; 1(3): 227-34.

44. de Luis DA, Sagrado MG, Conde R, Aller R, Izaola O, de la Fuente B, et al. Relation of resistin levels with cardiovascular risk factors, insulin resistance, and inflammation in naive diabetes obese patients. Diabetes Res Clin Pract 2010; 89(2): 110-4.

45. Straburzynska-Lupa A, Nowak A, Pilaczynska-Szczesniak L, Straburzynska-Migaj E, Romanowski W, Karolkiewicz J, et al. Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis. Clin Exp Rheumatol 2010; 28(1): 19-24.

46. Kopff B, Jegier A. Adipokines: adiponectin, leptin, resistin and coronary heart disease risk. Przegl Lek 2005; 62 (Suppl 3): 69-72.

47. Chen BH, Song Y, Ding EL, Roberts CK, Manson JE, Rifai N, et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 2009; 32(2): 329-34.

48. Chen C, Jiang J, Lu JM, Chai H, Wang X, Lin PH, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010; 299(1): H193-H201.

49. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007; 156(2): 279-84.

50. Kim DB, Oh YS, Yoo KD, Lee JM, Park CS, Ihm SH, et al. Passive smoking in never-smokers is associated with increased plasma homocysteine levels. Intern Heart J 2010; 51(3): 183-7.

51. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999; 19: 217-46.

52. Dominguez LJ, Galioto A, Pinoe A, Ferlisi A, Ciaccio M, Putignano E, et al. Age, homocysteine, and oxidative stress: relation to hypertension and type 2 diabetes mellitus. J Am Coll Nutr 2010; 29(1): 1-6.
کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی
اصول تنظیم قراردادها
آموزش مهارت های کاربردی در تدوین و چاپ مقاله